Abstract: The invention pertains to a catalyst at least comprising a hydrogenation metal component and a swelling synthetic clay consisting of elemental clay platelets, with the average diameter of the clay platelets not exceeding 1 micron and the average degree of stacking of the clay platelets not exceeding 20 platelets per stack. The catalyst is especially suitable for the hydroprocessing of hydrocarbon feeds, the term “hydroprocessing” encompassing all processes in which a hydrocarbon feed is treated with hydrogen. The clays which are suitable for use in the catalyst according to the invention may be prepared as described in Netherlands patent application No. 9401433.

Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.

Abstract: The present invention relates to a process for preparing a catalyst suitable for the hydroprocessing of heavy hydrocarbon feeds, which process comprises the steps of(i) if necessary removing carbonaceous and sulphurous deposits from waste catalyst by subjecting the waste catalyst to a thermal treatment,(ii) grinding the waste catalyst obtained in step (i),(iii) mixing the ground material obtained in step (ii) with a binder and, optionally, additives, and(iv) shaping the mixture to form a new catalyst,wherein the loss on ignition of the catalyst composition mixture at any point in the steps (ii), (iii), and (iv) is not higher than 70%.The process according to the invention is suitable, int. al., for the production of ebullated bed catalysts. In that case, it is envisaged to incorporate a macroporous additive into the catalyst composition.

Abstract: An immunotoxin molecule comprising an antibody specific for human CD 86 antigen located on the surface of a human cell, coupled to a toxin molecule or active fragment thereof, wherein the binding of the immunotoxin to the CD86 antigen results in the killing of CD86 expressing cell and pharmaceutical compositions and the use therefor to treat diseases of the immune system of warm-blooded animals.

Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract: The present invention relates to a process for preparing a hydroprocessing catalyst comprising the steps of subjecting a spent hydroprocessing catalyst comprising carbonaceous and sulphurous deposits to a thermal treatment to remove at least part of said deposits, grinding the thus obtained spent catalyst, mixing the ground hydroprocessing catalyst with at least one additive, and shaping the mixture of additive and ground hydroprocessing catalyst to form particles of a new hydroprocessing catalyst, with the spent hydroprocessing catalyst being subjected to a high-temperature calcination step carried out at a temperature in the range of 550-1000.degree. C. for a period sufficient to increase the MPD of the spent catalyst by at least 0.5 nm.The process according to the invention is particularly suitable for preparing ebullated bed catalysts from spent hydroprocessing catalysts.

Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract: Methods for preventing or treating an antibody-mediated disease in patient are presented, the methods comprising administration of a humanized monoclonal antibody or fragment thereof that is capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Humanized monoclonal antibodies and fragments useful in these methods are also presented.

Abstract: Methods for causing T cell anergy, treating allograft transplant rejection, treating graft versus host disease, and preventing or treating rheumatoid arthritis are presented, the methods comprising co-administration of a molecule that binds to the B7 antigen and an immunosuppressive agent.

Abstract: Anti-B7-1 antibodies or other B7-1 ligands may be used to prevent or treat a T-cell-mediated immune system disease in a patient or to induce antigen-specific tolerance.The anti-B7-1 antibodies may be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent is co-administered with the antibody.

Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract: The present invention relates to a method of generating antibodies directed against cell surface antigens. The method uses as immunogen recombinant insect cells into which have been transfected coding regions for a molecule containing a cell surface antigen. Host animals are immunized with these transfected insect cells to generate antibodies directed against the cell surface antigen. Antibody-producing cells from the host animal are used to generate monoclonal antibody-producing hybridoma cells. Sera and hybridoma supernatants can be tested for the presence of antibodies against the surface antigen, using the transfected cells in a screening assay.